SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pluristem Therapeutics
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
295 17 0 PSTI
Emcee:  FJB Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
95Pluristem Therapeutics Completes Dosing of First Group of Patients in Europe Witxcentral1-12/1/2009
94Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patiexcentral1-11/17/2009
93BUYINS.NET: 50.64% Of All NASDAQ Trading Tuesday Was Short Selling. DATE SYMBOxcentral1-10/21/2009
92Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adultxcentral1-10/21/2009
91Pluristem Therapeutics Will Present at the New England-Israel Life Sciences Summxcentral1-10/14/2009
90Pluristem Therapeutics to Raise $3.0 Million in Registered Direct Offering HAIxcentral1-10/6/2009
89It would be remiss not to post this news... but remember: (for as long as I havxcentral1-10/5/2009
88Pluristem Therapeutics Has Been Selected to Present at The Israeli Presidential xcentral1-9/29/2009
87Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cexcentral1-9/23/2009
86Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Prxcentral1-9/10/2009
85Pluristem Therapeutics Will Present Its Unique Placenta Derived Stem Cell Therapxcentral1-9/9/2009
84Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in Critical Lixcentral1-8/11/2009
83Pluristem’s Award from the Israeli Office of the Chief Scientist Increased to $2xcentral1-8/4/2009
82Pluristem Therapeutics Announces First Patient Enrollment in Phase I Clinical Trxcentral1-7/7/2009
81Pluristem Therapeutics Was Awarded a $1.9 Million Grant From the Office of the Cxcentral1-6/29/2009
80Pluristem Therapeutics Inc granted European regulatory approval for placental-dexcentral1-6/16/2009
79Pluristem Therapeutics to Present at the Second Annual Life Science Conference oxcentral1-6/11/2009
78Pluristem Therapeutics to Present at the 8th Israel Life Science Industry (ILSI)xcentral1-6/8/2009
77Stanford’s Professor John Cooke Joins Pluristem’s Scientific Advisory Board Busixcentral1-6/4/2009
76Pluristem Therapeutics to Present at the International Society for Stem Cell Resxcentral1-6/4/2009
75Pluristem Therapeutics Announces Major Clinical Site in North Carolina for PLX-Pxcentral1-5/14/2009
74Pluristem Therapeutics to Present at the Center for Finance Education Business Wxcentral1-5/12/2009
73Pluristem Therapeutics Announces $1.3 Million Securities Offering with Two Instixcentral1-5/6/2009
72Pluristem Therapeutics to Present at the 2009 BIO International Convention as Paxcentral1-5/5/2009
71Pluristem Therapeutics to Present Its Clinical Path at the International Societyxcentral1-4/29/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News